CoChat

Anti‐platelet therapy: cyclo‐oxygenase inhibition and the use of aspirin with particular regard to dual anti‐platelet therapy

Open access
Warner, Timothy D., Nylander, Sven, Whatling, Carl · 2011 · British Journal of Clinical Pharmacology
Cited by 245

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Aspirin and P2Y 12 antagonists are commonly used anti‐platelet agents. Aspirin produces its effects through inhibition of thromboxane A 2(TXA 2) production, while P2Y 12 antagonists attenuate the secondary responses to ADP released by activated platelets. The anti‐platelet effects of aspirin and a P2Y 12 antagonist are often considered to be separately additive. However, there is evidence of an overlap in effects, in that a high level of P2Y 12 receptor inhibition can blunt TXA 2 receptor signalling in platelets and reduce platelet production of TXA 2. Against this background, the addition of aspirin, particularly at higher doses, could cause significant reductions in the production of prostanoids in other tissues, e.g. prostaglandin I 2 from the blood vessel wall. This review summarizes the data from clinical studies in which dose‐dependent effects of aspirin on prostanoid production have been evaluated by both plasma and urinary measures. It also addresses the biology underlying the cardiovascular effects of aspirin and its influences upon prostanoid production throughout the body. The review then considers whether, in the presence of newer, more refined P2Y 12 receptor antagonists, aspirin may offer less benefit than might have been predicted from earlier clinical trials using more variable P2Y 12 antagonists. The possibility is reflected upon, that when combined with a high level of P2Y 12 blockade the net effect of higher doses of aspirin could be removal of anti‐thrombotic and vasodilating prostanoids and so a lessening of the anti‐thrombotic effectiveness of the treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2011.03943.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 245

Metadata

Authors
Warner, T. D., Nylander, S., & Whatling, C.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2011-09-09
Volume
72
Issue
4
Pages
619-633
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1608454038
Cited by
245
References
9
FWCI
3.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti‐platelet therapy: cyclo‐oxygenase inhibition and the use of aspirin with particular regard to dual anti‐platelet therapy. https://app.cochat.ai/papers/10.1111/j.1365-2125.2011.03943.x
The paper
Warner, T. D., Nylander, S., & Whatling, C. (2011). Anti‐platelet therapy: cyclo‐oxygenase inhibition and the use of aspirin with particular regard to dual anti‐platelet therapy. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2011.03943.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.